The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes.
Abstract
The amphipathic anthracycline base doxorubicin (DXR) was accumulated in the aqueous phase of the liposomes where it reached a level as high as 100-fold its concentration in the remote loading medium. Most of the intraliposomal DXR was present in an aggregated state. Efficient (>90%) and stable loading into the liposomes' and ligandoliposomes' aqueous phase was obtained by using gradients of ammonium sulfate in which the ammonium sulfate concentration in the liposomes was higher than its concentration in the extraliposomal medium [(NH4)2SO4)lip. ≫ [(NH4)2SO4)med.]. The “remote” loading is a result of the DXR exchange with ammonia from (NH4)2SO4. Both the ammonium and sulfate contribute to high level and stability of the loading. The ammonium sulfate gradient method differs from most other chemical approaches used for remote loading of liposomes since it neither requires to prepare the liposomes in acidic pH, nor to alkalinize the extraliposomal aqueous phase. Although most of the intraliposomal DXR is present in an aggregated gel-like state, the drug is bioavailable. This approach permits the preparation of DXR-loaded liposomes of a broad spectrum of types, sizes, and composition, including sterically-stabilized liposomes, immunoliposomes, and sterically-stabilized immunoliposomes. Due to the long shelf stability (>6 mo), no “bedside” remote loading is required immediately before patient treatment, and the formulation is ready for injection. The stable encapsulation of the doxorubicin in an aggregated form also permits freezing and lyophilization of the liposomes with only minimal drug release. The loading by ammonium sulfate gradient approach meets all pharmaceutical requirements; it has brought the clinical use of DXR-loaded sterically-stabilized liposomes to reality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
Self-citation
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
“Since the application of this approach to Doxil, which was initiated in 1987/1988, [48,55,56,60], our remote loading approaches for loading amphipathicweak bases or acidswere successfully employed for other drugs”
MethodSelf-citationDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationLiposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Self-citationShaping Cancer Nanomedicine: The Effect of Particle Shape on The In Vivo Journey of Nanoparticles
Toy, R., Peiris, P. M., Ghaghada, K. B., & Karathanasis, E. (2014) · Nanomedicine · doi:10.2217/nnm.13.191 · Cited by 570
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient
Fritze, A., Hens, F., Kimpfler, A., Schubert, R., & Peschka-Süss, R. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.05.028 · Cited by 416
The Liposomal Formulation of Doxorubicin
Abraham, S. A., Waterhouse, D. N., Mayer, L. D., Cullis, P. R., Madden, T. D., & Bally, M. B. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)91004-5 · Cited by 355
Zucker, D., Marcus, D., Barenholz, Y., & Goldblum, A. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.05.036 · Cited by 340
Self-citationAdvancement and applications of peptide phage display technology in biomedical science
Wu, C.-H., Liu, I.-J., Lu, R.-M., & Wu, H.-C. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0223-x · Cited by 339
Lentacker, I., Geers, B., Demeester, J., De Smedt, S. C., & Sanders, N. N. (2010) · Molecular Therapy · doi:10.1038/mt.2009.160 · Cited by 312
Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., & Allen, T. M. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00138-s · Cited by 309
Controlled targeting of liposomal doxorubicin via the folate receptor in vitro
Saul, J. M., Annapragada, A., Natarajan, J. V., & Bellamkonda, R. V. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00295-5 · Cited by 303
Charrois, G. J. R., & Allen, T. M. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2004.03.006 · Cited by 300
Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery
Almeida, B., Nag, O. K., Rogers, K. E., & Delehanty, J. B. (2020) · Molecules · doi:10.3390/molecules25235672 · Cited by 298
Conventional and Dense Gas Techniques for the Production of Liposomes: A Review
Meure, L. A., Foster, N. R., & Dehghani, F. (2008) · AAPS PharmSciTech · doi:10.1208/s12249-008-9097-x · Cited by 297
Nanoliposome technology for the food and nutraceutical industries
Khorasani, S., Danaei, M., & Mozafari, M. R. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.07.009 · Cited by 293
Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., & Zalipsky, S. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00085-h · Cited by 288
Chen, K.-J., Liang, H.-F., Chen, H.-L., Wang, Y., Cheng, P.-Y., Liu, H.-L., Xia, Y., & Sung, H.-W. (2013) · ACS Nano · doi:10.1021/nn304474j · Cited by 279
Ghoroghchian, P. P., Li, G., Levine, D. H., Davis, K. P., Bates, F. S., Hammer, D. A., & Therien, M. J. (2006) · Macromolecules · doi:10.1021/ma0519009 · Cited by 266
Drug delivery vehicles on a nano-engineering perspective
Felice, B., Prabhakaran, M. P., Rodríguez, A. P., & Ramakrishna, S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.04.049 · Cited by 253
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.
Lasic, D. D., Čeh, B., Stuart, M. C. A., Guo, L., Frederik, P. M., & Barenholz, Y. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00159-z · Cited by 209
Self-citationLipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Clerc, S., & Barenholz, Y. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00214-6 · Cited by 145
Self-citation
Metadata
- Authors
- Bolotin, E. M., Cohen, R., Bar, L. K., Emanuel, N., Ninio, S., Barenholz, Y., & Lasic, D. D.
- Venue
- Journal of Liposome Research
- Publisher
- Informa UK Limited
- Published
- 1994-01
- Volume
- 4
- Issue
- 1
- Pages
- 455-479
- ISSN
- 0898-2104 (ISSN-L)
- 1532-2394
- OpenAlex
- W2039350685
- Cited by
- 207
- References
- 1
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.